Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American ConferenceAlan Huber, J.K. Everett, Burcu Kolukısa et al.|Journal of Clinical Immunology|2021Cited by 28
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization studyPauline M. Ellerbroek, Leman Yel, Leif G. Hanitsch et al.|Immunotherapy|2024Cited by 5
Non-interventional post-marketing safety study on the long-term safety of HyQvia (global)Lina Morales Laguado, Leman Yel, Katharina Fielhauer et al.|DOAJ (DOAJ: Directory of Open Access Journals)|2018Cited by 0
60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study designRichard LWasserman, Zhaoyang Li, Helen L. Leavis et al.|Clinical Immunology|2024Cited by 0